Carisma Therapeutics, Inc. Common Stock
Symbol: CARM (NASDAQ)
0.28
▼ (-1.30%) -0.004
Company Description:
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Key Stats
- Today's Open: $0.275
- Today's High: $0.294
- Today's Low: $0.276
- Today's Volume: 531.03K
- Yesterday Close: $0.2837
- Yesterday High: $0.307501
- Yesterday Low: $0.2753
- Yesterday Volume: 1.03M
- Last Min Volume: 100
- Last Min High: $0.279
- Last Min Low: $0.279
- Last Min VWAP: $0.279
Company Profile
- Name: Carisma Therapeutics, Inc. Common Stock
- Website: https://www.carismatx.com
- Listed Date: 2023-03-08
- Location: PHILADELPHIA, PA
- Market Status: Active
- CIK Number: 0001485003
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $11.86M
- Round Lot: 100
- Outstanding Shares: 41.79M
- Asset Type: CS
RECENT FILINGS FOR CARM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-18 | RW | View |
| 2025-09-18 | 8-K | View |
| 2025-09-02 | SCHEDULE 13D/A | View |
| 2025-08-29 | SCHEDULE 13D/A | View |
| 2025-08-29 | S-4/A | View |
| 2025-08-29 | 425 | View |
| 2025-08-29 | 8-K | View |
| 2025-08-21 | SCHEDULE 13D/A | View |
| 2025-08-08 | 425 | View |
| 2025-08-08 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-07-31 | DEFA14A | View |
| 2025-07-21 | S-4 | View |
| 2025-07-15 | 425 | View |
| 2025-07-15 | 8-K | View |
| 2025-07-07 | DEF 14A | View |
| 2025-06-27 | PRE 14A | View |
| 2025-06-25 | 425 | View |
| 2025-06-23 | 425 | View |
| 2025-06-23 | 425 | View |
Latest News on CARM